TY - JOUR
T1 - Treatment of recurrent herpes simplex labialis with oral acyclovir
AU - Spruance, Spotswood L.
AU - Stewart, Jeffery C.B.
AU - Rowe, Nathaniel H.
AU - McKeough, Mark B.
AU - Wenerstrom, Gay
AU - Freeman, Donna J.
N1 - Funding Information:
Received 18 January 1989; revised 9 August 1989. Presented in part at the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 28 September-l October 1986, New Orleans. Each participant signed an Institutional Review Board-approved document of informed consent, and guidelines for human experimentation at each institution were followed. Supported in part bya grant from Burroughs Wellcome Co., Research Triangle Park, NC, and by grant RR-Q0064, Division of Research Resources, National Institutes of Health. Reprints and correspondence: Dr. S. L. Spruance, Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132.
PY - 1990/2
Y1 - 1990/2
N2 - In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97% of the patients, treatment started within 1 h of the first sign or symptom of a recurrence. The frequency of positive lesion virus cultures was significantly lower among acyclovir-treated subjects (29/114,25%) than among placebo-treated subjects (29/60,48%; P =.004). Drug treatment did not affect the development of lesions, measured by the frequency of macular and papular (aborted) lesions and mean maximum lesion size. However, acyclovir hastened lesion resolution among the patients who could start treatment in the prodrome or erythema lesion stage. For this group, the mean duration of pain was reduced by 36% (P =.02)and the mean healing time to loss of crust by 27% (P =.03). Thus, oral acyclovir alleviated some of the clinical manifestations of herpes simplex labialis.
AB - In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97% of the patients, treatment started within 1 h of the first sign or symptom of a recurrence. The frequency of positive lesion virus cultures was significantly lower among acyclovir-treated subjects (29/114,25%) than among placebo-treated subjects (29/60,48%; P =.004). Drug treatment did not affect the development of lesions, measured by the frequency of macular and papular (aborted) lesions and mean maximum lesion size. However, acyclovir hastened lesion resolution among the patients who could start treatment in the prodrome or erythema lesion stage. For this group, the mean duration of pain was reduced by 36% (P =.02)and the mean healing time to loss of crust by 27% (P =.03). Thus, oral acyclovir alleviated some of the clinical manifestations of herpes simplex labialis.
UR - http://www.scopus.com/inward/record.url?scp=0025159265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025159265&partnerID=8YFLogxK
U2 - 10.1093/infdis/161.2.185
DO - 10.1093/infdis/161.2.185
M3 - Article
C2 - 2153735
AN - SCOPUS:0025159265
SN - 0022-1899
VL - 161
SP - 185
EP - 190
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -